The ubiquitin proteasome pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 8, 2012, Pages 726-738

  Tu, Yaqin ^a   Chen, Cai ^a   Pan, Junru ^a   Xu, Junfa ^b   Zhou, Zhi Guang ^c   Wang, Cong Yi ^a,b,d  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cell cycle; DNA damage response; Tumorigenesis; Ubiquitin proteasome pathway; Ubiquitination

Indexed keywords

CELL CYCLE PROTEIN; DNA; PROTEASOME; UBIQUITIN;

CELL CYCLE; DNA DAMAGE; DNA REPAIR; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

CELL CYCLE; CELL CYCLE PROTEINS; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; HUMANS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 84870425303     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Shah SA, Potter MW and Callery MP. Ubiquitin proteasome pathway: implications and advances in cancer therapy. Surg Oncol 2001; 10: 43-52.
2. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Biochim Biophys Acta 2012; 1824: 3-13.
3. Burger AM and Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 2004; 40: 2217-2229.
4. Clague MJ and Urbe S. Ubiquitin: same molecule, different degradation pathways. Cell 2010; 143: 682-685.
5. Yang WL, Zhang X and Lin HK. Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development. Oncogene 2010; 29: 4493-4503.
6. Cook WJ, Jeffrey LC, Xu Y and Chau V. Tertiary structures of class I ubiquitin-conjugating enzymes are highly conserved: crystal structure of yeast Ubc4. Biochemistry 1993; 32: 13809-13817.
7. Pickart CM and Eddins MJ. Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta 2004; 1695: 55-72.
8. Kim JH, Park KC, Chung SS, Bang O and Chung CH. Deubiquitinating enzymes as cellular regulators. J Biochem 2003; 134: 9-18.
9. Park MT and Lee SJ. Cell cycle and cancer. J Biochem Mol Biol 2003; 36: 60-65.
10. Nakayama KI and Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369-381.
11. Mocciaro A and Rape M. Emerging regulatory mechanisms in ubiquitin-dependent cell cycle control. J Cell Sci 2012; 125: 255-263.
12. Skaar JR and Pagano M. Control of cell growth by the SCF and APC/C ubiquitin ligases. Curr Opin Cell Biol 2009; 21: 816-824.
13. Kurland JF and Tansey WP. Crashing waves of destruction: the cell cycle and APC(Cdh1) regulation of SCF(Skp2). Cancer Cell 2004; 5: 305-306.
14. Csikasz-Nagy A, Palmisano A and Zamborszky J. Molecular network dynamics of cell cycle control: transitions to start and finish. Methods Mol Biol 2011; 761: 277-291.
15. Egozi D, Shapira M, Paor G, Ben-Izhak O, Skorecki K and Hershko DD. Regulation of the cell cycle inhibitor p27 and its ubiquitin ligase Skp2 in differentiation of human embryonic stem cells. FASEB J 2007; 21: 2807-2817.
16. Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW and Elledge SJ. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 1996; 86: 263-274.
17. Hao B, Oehlmann S, Sowa ME, Harper JW and Pavletich NP. Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol Cell 2007; 26: 131-143.
18. Meyer HJ and Rape M. Processive ubiquitin chain formation by the anaphase-promoting complex. Semin Cell Dev Biol 2011; 22: 544-550.
19. Foe IT, Foster SA, Cheung SK, DeLuca SZ, Morgan DO and Toczyski DP. Ubiquitination of Cdc20 by the APC occurs through an intramolecular mechanism. Curr Biol 2011; 21: 1870-1877.
20. Toda K, Naito K, Mase S, Ueno M, Uritani M, Yamamoto A and Ushimaru T. APC/C-Cdh1-dependent anaphase and telophase progression during mitotic slippage. Cell Div 2012; 7: 4.
21. Yamasaki L and Pagano M. Cell cycle, proteolysis and cancer. Curr Opin Cell Biol 2004; 16: 623-628.
22. Abdou AG, Asaad NY, Abd El-Wahed MM, Samaka RM and Allah MS. The prognostic value of Skp2 expression in Egyptian diffuse large Bcell lymphoma. Appl Immunohistochem Mol Morphol 2012; 20: 47-55.
23. Wang Z, Gao D, Fukushima H, Inuzuka H, Liu P, Wan L, Sarkar FH and Wei W. Skp2: a novel potential therapeutic target for prostate cancer. Biochim Biophys Acta 2012; 1825: 11-17.
24. Chen G, Cheng Y, Zhang Z, Martinka M and Li G. Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival. PLoS One 2011; 6: e17578.
25. Einama T, Kagata Y, Tsuda H, Morita D, Ogata S, Ueda S, Takigawa T, Kawarabayashi N, Fukatsu K, Sugiura Y, Matsubara O and Hatsuse K. High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome. Pancreas 2006; 32: 376-381.
26. Traub F, Mengel M, Luck HJ, Kreipe HH and von Wasielewski R. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat 2006; 99: 185-191.
27. Shapira M, Ben-Izhak O, Slotky M, Goldin O, Lahav-Baratz S and Hershko DD. Expression of the ubiquitin ligase subunit cyclin kinase subunit 1 and its relationship to S-phase kinase protein 2 and p27Kip1 in prostate cancer. J Urol 2006; 176: 2285-2289.
28. Welcker M and Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008; 8: 83-93.
29. Smolders L and Teodoro JG. Targeting the anaphase promoting complex: common pathways for viral infection and cancer therapy. Expert Opin Ther Targets 2011; 15: 767-780.
30. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009; 361: 1475-1485.
31. Feng L and Chen J. The E3 ligase RNF8 regulates KU80 removal and NHEJ repair. Nat Struct Mol Biol 2012; 19: 201-206.
32. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358: 15-16.
33. Brooks CL and Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003; 15: 164-171.
34. Coutts AS, Adams CJ and La Thangue NB. p53 ubiquitination by Mdm2: a never ending tail? DNA Repair (Amst) 2009; 8: 483-490.
35. Kubbutat MH, Jones SN and Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
36. Yang Y, Li CC and Weissman AM. Regulating the p53 system through ubiquitination. Oncogene 2004; 23: 2096-2106.
37. Lakin ND and Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 1999; 18: 7644-7655.
38. Soussi T and Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007; 12: 303-312.
39. Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003; 3: 102-109.
40. Knights CD, Liu Y, Appella E and Kulesz-Martin M. Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification. J Biol Chem 2003; 278: 52890-52900.
41. Deng CX and Scott F. Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene 2000; 19: 1059-1064.
42. Cortez D, Wang Y, Qin J and Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999; 286: 1162-1166.
43. Mallery DL, Vandenberg CJ and Hiom K. Activation of the E3 ligase function of the BRCA1/ BARD1 complex by polyubiquitin chains. EMBO J 2002; 21: 6755-6762.
44. Greenberg RA, Sobhian B, Pathania S, Cantor SB, Nakatani Y and Livingston DM. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev 2006; 20: 34-46.
45. Wu W, Koike A, Takeshita T and Ohta T. The ubiquitin E3 ligase activity of BRCA1 and its biological functions. Cell Div 2008; 3: 1.
46. Zhang J and Powell SN. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 2005; 3: 531-539.
47. Yang ES and Xia F. BRCA1 16 years later: DNA damage-induced BRCA1 shuttling. FEBS J 2010; 277: 3079-3085.
48. Jiang J, Yang ES, Jiang G, Nowsheen S, Wang H, Wang T, Wang Y, Billheimer D, Chakravarthy AB, Brown M, Haffty B and Xia F. p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. Cancer Res 2011; 71: 5546-5557.
49. Feng Z, Kachnic L, Zhang J, Powell SN and Xia F. DNA damage induces p53-dependent BRCA1 nuclear export. J Biol Chem 2004; 279: 28574-28584.
50. Ahmed M, Lalloo F and Evans DG. Update on genetic predisposition to breast cancer. Expert Rev Anticancer Ther 2009; 9: 1103-1113.
51. Friedenson B. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer 2007; 7: 152.
52. Shakya R, Reid LJ, Reczek CR, Cole F, Egli D, Lin CS, deRooij DG, Hirsch S, Ravi K, Hicks JB, Szabolcs M, Jasin M, Baer R and Ludwig T. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science 2011; 334: 525-528.
53. Hoeller D and Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009; 458: 438-444.
54. Voges D, Zwickl P and Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999; 68: 1015-1068.
55. Frezza M, Schmitt S and Dou QP. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy. Curr Top Med Chem 2011; 11: 2888-2905.
56. Lecker SH, Goldberg AL and Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 2006; 17: 1807-1819.
57. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7: 9-16.
58. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 417-421.
59. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM and Perez-Soler R. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003; 9: 1145-1154.
60. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Pe trucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H and Richardson PG. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
61. Chen D, Frezza M, Schmitt S, Kanwar J and Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011; 11: 239-253.
62. Pray TR, Parlati F, Huang J, Wong BR, Payan DG, Bennett MK, Issakani SD, Molineaux S and Demo SD. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets. Drug Resist Updat 2002; 5: 249-258.
63. Di J, Zhang Y and Zheng J. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach. Curr Cancer Drug Targets 2011; 11: 987-994.
64. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV, Safiran YJ, Oberoi P, Kenten JH, Phillips AC, Weissman AM and Vousden KH. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7: 547-559.
65. Chen L, Agrawal S, Zhou W, Zhang R and Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci U S A 1998; 95: 195-200.
66. Tortora G, Caputo R, Damiano V, Bianco R, Chen J, Agrawal S, Bianco AR and Ciardiello F. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int J Cancer 2000; 88: 804-809.
67. Zhang R, Wang H and Agrawal S. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Curr Cancer Drug Targets 2005; 5: 43-49.
68. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ and Pavletich NP. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274: 948-953.
69. Shinohara T and Uesugi M. [In-vivo activation of the p53 pathway by small-molecule antagonists of MDM2]. Tanpakushitsu Kakusan Koso 2007; 52: 1816-1817.
70. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR, Maguire D, Lattanze J, Franks CF, Zhao S, Ramachandren K, Bylebyl GR, Zhang M, Manthey CL, Petrella EC, Pantoliano MW, Deckman IC, Spurlino JC, Maroney AC, Tomczuk BE, Molloy CJ and Bone RF. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 2005; 48: 909-912.
71. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A and Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10: 1321-1328.
72. Ding K, Lu Y, Nikolovska-Coleska Z, Qiu S, Ding Y, Gao W, Stuckey J, Krajewski K, Roller PP, Tomita Y, Parrish DA, Deschamps JR and Wang S. Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc 2005; 127: 10130-10131.
73. Xu GW, Ali M, Wood TE, Wong D, Maclean N, Wang X, Gronda M, Skrtic M, Li X, Hurren R, Mao X, Venkatesan M, Beheshti Zavareh R, Ketela T, Reed JC, Rose D, Moffat J, Batey RA, Dhe-Paganon S and Schimmer AD. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 2010; 115: 2251-2259.
74. Yang Y, Kitagaki J, Dai RM, Tsai YC, Lorick KL, Ludwig RL, Pierre SA, Jensen JP, Davydov IV, Oberoi P, Li CC, Kenten JH, Beutler JA, Vousden KH and Weissman AM. Inhibitors of ubiquitinactivating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 2007; 67: 9472-9481.
75. Ungermannova D, Parker SJ, Nasveschuk CG, Chapnick DA, Phillips AJ, Kuchta RD and Liu X. Identification and mechanistic studies of a novel ubiquitin E1 inhibitor. J Biomol Screen 2012; 17: 421-434.
76. Luise C, Capra M, Donzelli M, Mazzarol G, Jodice MG, Nuciforo P, Viale G, Di Fiore PP and Confalonieri S. An atlas of altered expression of deubiquitinating enzymes in human cancer. PLoS One 2011; 6: e15891.
77. Nicholson B, Marblestone JG, Butt TR and Mattern MR. Deubiquitinating enzymes as novel anticancer targets. Future Oncol 2007; 3: 191-199.
78. Allende-Vega N, Sparks A, Lane DP and Saville MK. MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene 2010; 29: 432-441.
79. Brummelkamp TR, Nijman SM, Dirac AM and Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003; 424: 797-801.
80. Oosterkamp HM, Neering H, Nijman SM, Dirac AM, Mooi WJ, Bernards R and Brummelkamp TR. An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. Br J Dermatol 2006; 155: 182-185.
81. Li Z, Wang D, Messing EM and Wu G. VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha. EMBO Rep 2005; 6: 373-378.
82. Lee BH, Lee MJ, Park S, Oh DC, Elsasser S, Chen PC, Gartner C, Dimova N, Hanna J, Gygi SP, Wilson SM, King RW and Finley D. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010; 467: 179-184.
83. Stevenson LF, Sparks A, Allende-Vega N, Xirodimas DP, Lane DP and Saville MK. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J 2007; 26: 976-986.